Compare Ascendis Pharma A/S (ASND) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Weibo Corp — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Weibo Corp trades at $7.69 (market cap $1.89B). The key difference: Ascendis Pharma A/S is far larger — about 9.4× Weibo Corp's market cap, and Weibo Corp pays a 7.89% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WB | |
|---|---|---|
Market Cap | $17.74B | $1.89B |
Sector | Health | Media |
52-Week High | $277.18 | $12.83 |
52-Week Low | $163.32 | $7.20 |
Enterprise Value | $18.11B | $1.16B |
Dividend Yield | — | 7.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Weibo (WB) trades at $7.72 with a bullish technical signal and strong valuation metrics, including a P/E of 5.41 and P/B of 0.49. Recent earnings missed estimates in three consecutive quarters, but the company maintains robust profitability with a 21.15% net income margin. A dividend of $0.61 was declared for H1 2026, supporting shareholder returns amid competitive pressures.
The stock presents value with deep undervaluation relative to cash flows and balance sheet strength, though user engagement challenges and rivalry from Douyin pose growth risks. Analyst consensus is mixed with 45% buy ratings, highlighting potential upside if execution improves, but investors face headwinds from China's regulatory environment and advertising volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
